glp-1 impact on digestion Intestinal glucagon-like peptide-1 effects food intake: Physiological relevance and emerging mechanisms GLP-1/glucagon receptor co-agonism for treatment

Emerging and Approved Therapeutic Peptides: Mechanisms, Clinical Uses, Safety Profiles, and Regulatory Status Across Health Conditions Abstract Therapeutic peptides represent a rapidly growing class of pharmaceutical agents that bridge the gap between small molecule drugs and large protein therapeutics

That doesnt sound like much, but its surprisingly difficult

In this analysis, we included the negative allosteric modulators NNC0640 (PDB: 5VEX) and PF-06372222 (PDB: 6KJV), the peptide agonists GLP-1 (7-36) (PDB: 6X18), exenatide (PDB: 7LLL) and semaglutide (PDB: 7KI0) as well as the small molecule agonist danuglipron (PDB: 6X1A) (Supplementary Data 1)

and infertility

Weight-loss drugs are driving new consumption patterns GLP-1s rewire how users experience food

Despite employee demand, companies are considering ways to tweak or eliminate coverage